10-Q · May 14, 2026
Clene Inc. for Q1 2026 reported a significant decline in revenue and continued operating losses, with total revenue decreasing 81% to $5 million from the previous year. The company incurred a net loss of $8.1 million…
Earnings analysis · 10-Q
CLNN earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The provided extract does not contain the June 30, 2026 income statement, balance sheet, cash-flow statement, or segment disclosures, so current-period revenue, margins, EPS, liquidity, debt, inventory, receivables and…
Read full summary
The provided extract does not contain the June 30, 2026 income statement, balance sheet, cash-flow statement, or segment disclosures, so current-period revenue, margins, EPS, liquidity, debt, inventory, receivables and free cash flow cannot be quantified. The principal disclosed development is that controls remained ineffective as of June 30, 2026, with material weaknesses spanning the control environment, accounting controls and IT general controls. Remediation continued during 2026, but the unresolved weaknesses represent a significant financial-reporting risk.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Internal-control remediation continues
Management stated that remediation activities continued during 2026, including plans to add technical accounting resources and continue using external consultants until sufficient resources are available.
-
No material legal proceedings reported
The filing reported no material pending legal proceedings as of June 30, 2026.
-
No insider trading arrangements reported
No officers or directors adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the three months ended June 30, 2026.
What to watch
-
Material weaknesses remain unresolved
As of June 30, 2026, management concluded that disclosure controls and procedures were not effective because of material weaknesses in the control environment, control activities, and information and communication.
-
IT control deficiencies create reporting risk
The filing identifies four IT general-control areas requiring improvement: user access, program change management, computer operations and backup monitoring, and program development testing and approval. Each deficiency could result in a material misstatement that is not timely prevented or detected.
-
Existing 10-K risks remain applicable
The company stated that there had been no material changes to its risk factors since the 2025 Form 10-K filed March 17, 2026; therefore, the previously disclosed risks remain applicable.
Management's outlook
The provided 10-Q extract does not include quantitative revenue or EPS guidance. No explicit outlook was identified.
Earlier filings 4
10-K · March 17, 2026
Clene positions itself as a first-mover developer of clean-surfaced nanocrystal (CSN®) therapeutics led by lead asset CNM‑Au8 for ALS, MS and PD, and supplements/dietary products via its dOrbital/4Life relationships.…
10-Q · August 14, 2025
Clene reported a dramatic revenue decline to $27,000 in Q2 2025 and a quarterly net loss of $7.419 million (EPS $(0.78)), driven by minimal product/royalty sales and continued R&D and G&A spend. Management generated…
10-Q · May 7, 2025
Clene reported total revenue of $81,000 for the three months ended March 31, 2025, up $8,000 from $73,000 in Q1 2024. Net loss narrowed sharply to $(751,000) (EPS $(0.09)) from $(11,080,000) (EPS $(1.73)) in the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.